Cullinan Therapeutics said it has completed an FDA new drug application filing for zipalertinib with chemotherapy, advancing the lung cancer treatment into U.S.

Cullinan Therapeutics said it has completed an FDA new drug application filing for zipalertinib with chemotherapy, advancing the lung cancer treatment into U.S. regulatory review. The candidate targets NSCLC with EGFR exon 20 insertion mutations and is partnered with Taiho.